Современные представления об антибиотикорезистентности и антибактериальной терапии сальмонеллёзов

Клиническая Микробиология и Антимикробная Химиотерапия. 2009; 11(4):305-326

​ Иванов А.С.
сальмонеллы Salmonella enterica резистентность брюшной тиф антибактериальная терапия
Раздел
Болезни и возбудители
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2009; 11(4):305-326

Аннотация

В обзоре представлены краткие сведения по эпидемиологии сальмонеллёзов, а также современная классификация и номенклатура сальмонелл. Приведены основные механизмы резистентности сальмонелл к антибиотикам и их распространённость. Подробно описаны данные по антибиотикорезистентности сальмонелл с учётом наиболее распространенных серотипов S. enterica, а также представлены международные рекомендации по рутинному определению чувствительности. Рассмотрены показания к антибактериальной терапии инфекций и оптимизация выбора антимикробных препаратов для лечения инфекций, вызванных нетифоидными серотипами сальмонелл, а также брюшного тифа/паратифов. Особое внимание уделено современным схемам антибактериальной терапии сальмонеллёзной инфекции, основанным на экспериментальных и клинических данных.

  • 1. Pessoa-Silva C.L., Toscano C.M., Moreira B.M., et al. Infection due to extended-spectrum β-lactamase-producing Salmonella enterica subsp enterica serotype infantis in a neonatal unit. J Pediatr 2002; 141:381-7.
  • 2. Nataro J.P., et al. Escherichia, Shigella and Salmonella. In: Murray P.R., e.a., eds. Manual of Clinical Microbiology. 9-th ed. Washington DC: ASM Press. 2007. P. 670-87.
  • 3. Parry C.M. Management of multiple drug-resistant Salmonella infections. In: Gillespie SH., ed. Management of Multiple Drug-Resistance Infections. Humana Press Inc., Totowa. 2004.P.189-208.
  • 4. Threlfall E.J., Fisher I.S.T., Berghold C., Edwards G., et al. Antimicrobial drug resistance in isolates of Salmonella enterica from cases of salmonellosis in humans in Europe in 2000: results of international multi-centre surveillance. Euro Surveill. 2003;8(2):41-5.
  • 5. Pegues D.A., Ohl M.E., Miller S.I. Salmonella species, including Salmonella typhi. In: Mandell GL, Bennett JE, Dolin R: Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases. Ed.
  • 6. Philadelphia: Elsevier Churchill Livingstone, 2005.P.2636-54. 6. Parry C.M., Hien T.T., Dougan G., White N.J., Farrar J.J. Typhoid fever. N Engi J Med 2002;347:1770-82.
  • 7. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001; 32:263-9.
  • 8. Ramos J.M., Garcia-Corbeira P., Aguado J.M., et al. Clinical significance of primary versus secondary bacteraemia due to nontyphoid Salmonella in patients without AIDS. Clin Infect Dis 1994; 19:777-80.
  • 9. Shimoni Z., Pitlik S., Leibovici L., et al. Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome. Clin Infect Dis 1999; 28:822-7.
  • 10. Chiu C.-H., Su L.-H., Chu C. Salmonella enterica serotype Choleraesuis: epidemiology, pathogenesis, clinical disease and treatment. Clin Microb Rev. 2004;17(2):311-22.
  • 11. Sirinavin S., Jayanetra P., Layangkul T. Predictors for extraintestinal infection in Salmonella enteritis in Thailand. Pediatr. Infect. Dis. J. 1988;7:44-8.
  • 12. Cohen J.I., Barllett J.A., Curey R. Extra-intestinal manifestations of Salmonella infections. Medicine (Baltimore). 1987;66:349-88.
  • 13. Jacobson M.A., Hahan S.M., Gerberding J.L., et al. Ciprofloxacin for Salmonella bacteremia in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;110:1027-9.
  • 14. Vugia, D.J., Samuel M., Farley M.M., et al. Invasive Salmonella infections in the United States, FoodNet, 1996-1999: incidence, serotype distribution, and outcome. Clin Infect Dis 2004; 38 (Suppl. 3):S149-S156.
  • 15. Chiu C.H., Su L.H., Chu C., et al. Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin. The Lancet. 2004;363:1285-6.
  • 16. Threlfall E.J. Antimicrobial drug resistance in Salmonella: problems and perspectives in food- and water-borne infections. FEMS Microbiol Rev 2002; 26:141-8.
  • 17. Jean S.-S., Wang J.-Y., Hsueh P.-R. Bacteremia caused by Salmonella enterica serotype Choleraesuis in Taiwan. J Microbiol Immunol Infect 2006; 39:358-65.
  • 18. Soravia-Dunand V.A., Loo V.G., Salit I.E. Aortitis due to Salmonella: report of 10 cases and comprehensive review of the literature. Clin Infect Dis 1999; 29:862-8.
  • 19. Prager R., Rabsch W., Streckel W., et al. Molecular properties of Salmonella enterica serotype Paratyphi B distinguish between its systemic and its enteric pathovars. J Clin Microbiol 2003; 41:4270-8.
  • 20. Farmer III J.J., Boatwricht K.D., Janda M.J. Enterobacteriaceae. Introduction and identification. In: Murray P.R., e.a., eds. Manual of Clinical Microbiology. 9-th ed. Washington DC: ASM Press, 2007. P. 649-69.
  • 21. Parkhill J., Dougan G., James K.D., et al. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 2001; 413:848- 52.
  • 22. Shanahan P.M.A., Karamat K.A., Thomson C.J., Amyes S.G.B. Characterization of multi-drug resistant Salmonella typhi isolated from Pakistan. Epidemiol Infect 2000; 124:9-16.
  • 23. Threlfall E.J. Multiresistant Salmonella typhimurium DT104: a truly international clone. J Antimicrob Chemother 2000; 46:7-10.
  • 24. Lindsay E.A., Lawson A.J., Walker R.A., et al. Molecular characterisation of a multiresistant strain of Salmonella enterica serotype typhimurium DT204b responsible for an international outbreak of salmonellosis: importance of electronic exchange of gel data for outbreak investigations. Emerg Infect Dis 2002; 8:732-4.
  • 25. Wall P.G., Morgan D., Lamden K., et al. A case control study of infection with an epidemic strain of multiresistant Salmonella typhimurium DT104 in England and Wales. Commun Dis Rep CDR Rev 1994;4:R130-R135.
  • 26. Glynn M.K., Bopp C., Dewitt W., et al. Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N. Engl. J. Med. 1998;338:1333-8.
  • 27. Verdet C., Arlet G., Barnaud G., Lagragnge P.H., Philippon A. A novel integron in Salmonella enterica serovar enteritidis, carrying the bla(DHA-1) gene and its regulator gene ampR, originated from Morganella morganii. Antimicrob Agent Chemother 2000; 44:222-5.
  • 28. Gaillot O., Clement C., Simonet M., Philippon A. Novel transferable β-lactam resistance with cephalosporinase characteristics in Salmonella enteritidis. J Antimicrob Chemother 1997; 39:85-7.
  • 29. Dunne E.E., Fey P.D., Kludt P., et al. Emergence of domestically-acquired ceftriaxone-resistant Salmonella infections associated with AmpC β-lactamase. JAMA 2000; 284:3151-6.
  • 30. Hanson N.D., Moland E.S., Hossain A., et al. Unusual Salmonella enterica serotype typhimurium isolate producing CMY-7, SHV-9 and OXA-30 β-lactamases. J Antimicrob Chemother 2002; 49:1011-4.
  • 31. Armand-Lefevre L., Leflon-Guibout V., Bredin J., et al. Imipenem resistance in Salmonella enterica serovar wein related to porin loss and CMY-4 β-lactamase production. Antimicrob Agents Chemother 2003; 47:1165-8.
  • 32. Gaillot O., Clement C., Simonet M., Philippon A. Novel transferable β-lactam resistance with cephalosporinase characteristics in Salmonella enteritidis. J Antimicrob Chemother 1997; 39:85-7.
  • 33. Su L.H., Wu T.L., Chia J.H., et al. Increasing ceftriaxone resistance in Salmonella isolates from university hospital in Taiwan. J Antimicrob Chemother 2005; 55:846-52.
  • 34. Threlfall E.J., Skinner J.A., Graham A., et al. Resistance to ceftriaxone and cefotaxime in non-typhoidal Salmonella enterica in England and Wales. J Antimicrob Chemother 2000; 46:860-2.
  • 35. Villa L., Mammina C., Miriagou V., et al. Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype enteritidis clinical isolates in southern Italy. J Clin Microbiol 2002; 40:2662-5.
  • 36. Molbak K., Baggesen D.L., Aarestrup F.M., et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. N Engl J Med 1999; 341:1420-5.
  • 37. Ridley A., Threlfall E.J. Molecular epidemiology of antibiotic resistance genes in multire-sistant Salmonella typhimurium DT104. Microb Drug Resist 1998; 2:113-8.
  • 38. Lawson A.J., Dassama M.U., Ward L.R., Threlfall E.J. Multiply resistant (MR) Salmonella enterica serotype typhimurium DT 12 and DT 120: a case of MR DT 104 in disguise? Emerg Infect Dis 2002; 8:434-6.
  • 39. Boyd D., Cloeckaert A., Chaslus-Danela E., Mulvey M.R. Characterization of variant Salmonella genomic island 1 multidrug resistance regions from serovars typhimurium DT104 and agona. Antimicrob Agents Chemother 2002; 46:1714-22.
  • 40. Meunier D., Boyd D., Mulvey M.R., et al. Salmonella enterica serotype typhimurium DT 104 antibiotic resistance genomic island 1 in serotype paratyphi B. Emerg Infect Dis 2002;8:430-3.
  • 41. Nikaido H., Basina M., Nguyen V., Rosenberg E.Y. Multydrug efflux pump AcrAB of Salmonella typhimurium excretes only those beta-lactam antibiotics containing lipophilic side chains. J Bacteriol 1998; 180:4686-92.
  • 42. Casin I., Breuil J., Darchis J.P., Guelpa C., Collatz E. Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in Salmonella enterica typhimurium isolates in humans. Emerg Infect Dis 2003; 9:1455-7.
  • 43. Archambaud M., Gerbaud G., Labau E., Marty N., Courvalin P. Possible in-vivo transfer of β-lactamase TEM-3 from Klebsiella pneumoniae to Salmonella kedougou. J Antimicrob Chemother 1991; 27:427-36.
  • 44. Tassios P.T., Gazouli M., Tzelepi E., et al. Spread of Salmonella typlnmurium clone resistant to expanded-spectrum cephalosporins in three European countries. J Clin Microbiol 1999; 37:3774-7.
  • 45. Datta N., Richards H., Datta C. Salmonella typhi in vivo acquires resistance to both chloramphenicol and cotrimoxazole. Lancet 1981; 1:1181-3.
  • 46. Schwalbe R., Hoge C.W., Morris J.G., O’Halon P.N. Craw­ford RA, Gilligan PH. In vivo selection for transmissible drug resistance in Salmonella typhi during antimicrobial therapy. Antimicrob Agents Chemother 1990; 34:161-3.
  • 47. Aarestrup F.M., Wiuff C., Molbak K., Threlfall E.J. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 2003; 47:827-9.
  • 48. Davis M.A., Hancock D.D., Besser T.E. Multiresistant clones of Salmonella enterica: the importance of dissemination. J Lab Clin Med 2002; 140:135-41.
  • 49. Llanes C., Kirchgesner V., Plesiat P. Propagation of TEM- and PSE-type β-lactamases among amoxycillinresistant Salmonella spp. isolated in France. Antimicrob Agents Chemother 1999; 43:2430-36.
  • 50. Ling J.M., Zhou G-M, Woo T.H.S, French G.L. Antimicrobial susceptibilities and β-lactamase production of Hong Kong isolates of gastroenteric salmonellae and Salmonella typhi. J Antimicrob Chemother 1991; 28:877-85.
  • 51. Ribot E.M., Wierzba R.K., Angulo F.J., Barrett T.J. Salmonella enterica serotype typhimurium DT104 isolated from humans, United States, 1985,1990, and 1995. Emerg Infect Dis 2002;8:387-91.
  • 52. Piddock L.J.V. Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. FEMS Microbiol Rev 2002; 26:3-16.
  • 53. Winokur P.L., Brueggemann A., DeSalvo D.L., et al. Animal and human multidrug-resistant cephalosporinresistant Salmonella isolates expressing a plasmid mediated CMY-2 AmpC β-lactamase. Antimicrob Agents Chemother 2000; 44:2777-83.
  • 54. Kadhiravan T., Wig N., Kapil A., et al. Clinical outcomes in typhoid fever: adver­se impact of infection with nalidixic acid-resistant Salmo­nella typhi. BMC Infectious Diseases. 2005;5:37.
  • 55. Nakaya H., Yasuhara A., Yoshimura K., et al. Life-threatening infantile diarrhoea from fluoroquinolone resistant Salmonella enterica typhimurium with mutations in both gyrA and parC. Emerg Infect Dis 2003; 9:255-7.
  • 56. Varma J.K., Molbak K., Barrett T.J., Angulo F.J., et al. Antimicrobial-resistant nontyphoidal Salmonella is assotiated with excess bloodstream infections and hospitalizations. J Infect Dis 2005;191:554-61.
  • 57. Egorova S., Kaftyreva L., Grimont P.A., Weill F.X. Prevalence and characterization of extended-spectrum cephalosporin-resistant nontyphoidal Salmonella isolates in adults in Saint Petersburg, Russia (2002-2005). Microb Drug Resist 2007;13(2):102-7.
  • 58. Ko W.C., Yan J.J., Yu W.L., et al. A new therapeutic challenge for old pathogens: community-acquired invasive infections caused by ceftriaxone- and ciprofloxacinresistant Salmonella enterica serotype Choleraesuis. Clin Infect Dis 2005; 40:315-8.
  • 59. Jean S.S., Lee Y.T., Guo S.M., Hsueh P.R. Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype Choleraesuis treated successfully with imipenem. J Infect 2005; 51:163-5.
  • 60. Yan J.J., Chiou C.S., Lauderdale T.L., et al. Cefalosporin and ciprofloxacin resistance in Salmonella, Taiwan. Emerg Infect Dis 2005; 11:947-50.
  • 61. Szych J., Cieslik A., Paciorek J., Kaluzewski S. Antibiotic resistance in Salmonella enterica subsp. enterica strains isolated in Poland from 1998 to 1999. Int J Antimicrob Agents 2001; 18:37-42.
  • 62. Yildirmak T., Yazgan A., Ozcengiz G. Multiple drug resistance patterns and plasmid profiles of non-typhi salmonellae in Turkey. Epidemiol Infect 1998; 121:303-7.
  • 63. Rastegar L.A., Validi N., Ghaffarzadeh K., Shamshiri A.R. In vitro activity of cefixime versus ceftizoxime against Salmonella typhi. Pathol Biol (Paris) 1997; 45:415-9.
  • 64. Yang Y.J., Liu C.C., Wang S.M., et al. High rates of antimicrobial resistance among clinical isolates of nontyphoidal Salmonella in Taiwan. Eur J Clin Microbiol Infect Dis 1998; 17:880-3.
  • 65. Griggs D.J., Gensberg K., .Piddock L.J. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from human and animals. Antimicrob Agents Chemother 1996; 40:1009-13.
  • 66. Threlfall E.J., Skinner J.A., Ward L.R. Detection of decreased susceptibility to ciprofloxacin in Salmonella enterica serotypes typhi and paratyphi A. J Antimicrob Chemother 2001; 48:740-1.
  • 67. Chinh N.T., Parry C.M., Ly N.T., et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother. 2000; 44:1855-9.
  • 68. Wain J., Hoa N.T.T., Chinh N.T., et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis. 1997; 25:1404-10.
  • 69. Heurtin-Le Corre C., Donnio P-Y., Perrin M., et al. Increasing incidence and comparison of nalidixic acidresistant Salmonella enterica subsp. enterica serotype typhimurium isolates from human and animals. J Clin Microbiol. 1999; 37:266-9.
  • 70. Molbak K., Gerner-Smidt, Wegener H.C. Increasing quinolone resistance in Salmonella enterica serotype enteritidis. Emerg Infect Dis. 2002; 8:514-5.
  • 71. Chiu C.H., Wu T.L., Su L.H., et al. The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype choleraesuis. N Engi J Med. 2002; 346:413-9.
  • 72. Heisig P. High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes. J Antimicrob Chemother 1993; 32:367-77.
  • 73. Baucheron S., Imberechts H., Cahslus-Danda E., Clockaert A. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist 2002; 8:281-9.
  • 74. Mehta G., Randhawa V.S., Mohapatra N.P. Intermediate susceptibility to ciprofloxacin in Salmonella typhi strains in India. Eur J Clin Microbiol 2001; 20:760-1.
  • 75. Tran J.H., Jacoby G.A. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002; 99(8):5638–42.
  • 76. Malorny B., Schroeter A., Helmuth R. Incidence of quinolone resistance over the period 1986 to 1998 in veterinary Salmonella isolates from Germany. Antimicrob Agents Chemother 1999; 43:2278-82.
  • 77. Hakanen A., Kotilainen P., Jalava J., et al Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 1999; 37:3572-7.
  • 78. Morisini MI, Blazquez J, Negri MC, et al. Characterisation of a nosocomial outbreak involving an epidemic plasmid encoding for TEM-27 in Salmonella enterica subspecies enterica serotype othmarschen. J Infect Dis 1996; 174:1015-20.
  • 79. Mathai D., Toleman M.A., Walsh T.R., Jones R.N. Molecular determination of β-lactamases (BL) types found in Salmonella spp. isolated in India: report for the MYSTIC programme (2001). In: Program and Abstracts of the 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy. San Diego, CA: American Society of Microbiology, 2002; Abstract C2-1276:104.
  • 80. Otkun M., Erdem B., Akata F., et al. Antibiotic resistance patterns and plasmid profiles of Salmonella typhimurium isolates in Turkey. Eur J Clin Microbiol Infect Dis 2001; 20:206-9.
  • 81. Bhutta Z.A., Farooqui B.J., Sturm A.W. Eradication of a multiple drug resistant Salmonella paratyphi A causing meningitis with ciprofloxacin. J Infect 1992; 25:215-9.
  • 82. Saha S.K., Taukder S.Y., Islam M., Saha S. A highly ceftriaxone-resistant Salmonella typhi in Bangladesh. Pediatr Infect Dis J 1999;18:387.
  • 83. Clinical and Laboratory Standards Institute. Perfomance Standards for Antimicrobial Susceptibility Testing; 16- th Informational Supplement. CLSI document M100- S16. 2006.Vol. 26 №. 3.
  • 84. Neill M.A., Opal S.M., Heelan J., et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during and outbreak in health care workers. Ann Intern Med 1991; 114:195-9.
  • 85. Thielman N.M., Guerrant R.L. Clinical practice. Acute infectious diarrhea. N Engl J Med 2004; 350(1):38-47.
  • 86. Sirinavin S., Garner P. Antibiotics for treating Salmonella gut infections. Cochrane Database Syst Rev 2000; 2: CD001167.
  • 87. Voltersvik P., Halstensen A., Langeland N., Solberg C.O., et al. Eradication of non-typhoid salmonellae in acute enteritis after therapy with ofloxacin for 5 and 10 days. J Antimicrob Chemother 2000; 46:457-9.
  • 88. Hamer D.H. Bacterial and viral diarrhea. In: Baddour L.M., Gorbach S.L., eds. Therapy of infectious diseases. Philadelphia: W.B. Saunders Company, 2003. p. 399-414.
  • 89. Halstensen A., Voltersvik P., Gossius G., et al. Doubleblind comparison of ofloxacin for 3 days and placebo in acute bacterial enteritis. Drugs. 1995; 49(Suppl. 2):454-6.
  • 90. Akalin H.E. Role of quinolones in the treatment of diarrhoeal diseases. Drugs. 1995; 49(Suppl. 2):128-31.
  • 91. Sirinavin S., Pokawattana L., Bangtrakulnondh A. Duration of nontyphoidal Salmonella carriage in asymptoma­tic adults. Clin Infect Dis. 2004;38:1644-5.
  • 92. Ball P., Mandell L., Niki Y., Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999;21(5):407-21.
  • 93. Danisovicova A., Brezina M., Belan S., et al. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy. A multicenter survey. Chemotherapy. 1994;40(3):209-14.
  • 94. Chysky V., Kapila K., Hullmann R., et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection. 1991;19(4):289-96.
  • 95. Chiu C.H., Lin T.Y., Ou J.T. In vitro evaluation of intracellular activity of antibiotics against non-typhoid Salmonella. Int J Antimicrob Agents 1999; 12:47-52.
  • 96. Chiu C., Lin T.Y., Ou J.T. A clinical trial comparing oral azithromycin, cefixime and no antibiotics in the treatment of acute uncomplicated Salmonella enteritis in children. J Paediatr Child Health 1999; 35:372-4.
  • 97. Wang J-H., Liu Y-C., Yen M-Y., et al. Mycotic aneurysm due to non-typhi Salmonella: report of 16 cases. Clin Infect Dis 1996; 23:743-7.
  • 98. Thapar N., Sanderson I.R. Diarrhoea in children: an interface between developing and developed countries. Lancet 2004; 363:641-53.
  • 99. Glynn M.K., Reddy V., Hutwagner L., et al. Prior antimicrobial agent use increases the risk of sporadic infections with multidrug-resistant Salmonella enterica serotype Typhimurium: a FoodNet case-control study, 1996-1997. Clin Infect Dis 2004; 38:S227-36.
  • 100. Hung C.C., Hung M.N., Hsueh P.R., et al. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance. Clin Infect Dis 2007; 45(Suppl 2):e60-7.
  • 101. Hamer D.H., Gorbach S.L. Use of the quinolones for treatment and prophilaxis of bacterial gastrointestinal infections. In: Andriole VT, ed. The quinolones. 3rd ed. San Diego: Academic Press, 2000. P. 303-23.
  • 102. Moss P. Infections of the gastrointestinal tract. In: Finch R.G., Greenwood D., Norrby S.R., and Whitley R.J., eds. Antibiotics and Chemotherapy: anti-infective agents and their use in therapy. 8-th ed. London: Churchill Livingstone, 2003; p. 667-81.
  • 103. Soe G.B., Overturf G.D. Treatment of typhoid fever and other systemic salmonelloses with cefotaxime, ceftriaxone, cefoperazone, and other newer cephalosporins. Rev Infect Dis 1987; 9:719-36.
  • 104. Dutta P., Rasaily R., Saha M.R., et al. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob Agents Chemother 1993; 37:1197-9.
  • 105. Punjabi N.H., Hoffman S.L., Edman D.C., et al. Treatment of severe typhoid fever in children with high dose dexamethasone. Pediatr Infect Dis J 1988; 7:598- 600.
  • 106. Seoud M., Saade G., Uwaydah M., Azoury R. Typhoid fever in pregnancy. Obstet Gynecol 1988;71:711-4.
  • 107. Islam A., Butler T., Kabir I., Alam N.H. Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial. Antimicrob Agents Chemother 1993; 37:1572-5.
  • 108. Phuong C.X.T., Kneen R., Nguyen T.A., et al. Dong Nai Typhoid Study Group. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. Pediatr Infect Dis J 1999; 18:245-8.
  • 109. Bhutta Z.A., Khan I.A., Molla A.M. Therapy of multidrug-resistant typhoid fever with oral cefixime versus intravenous ceftriaxone. Pediatr Infect Dis J 1994; 13:990-4.
  • 110. Frenck R.W Jr., Nakhia I., Sultan Y. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. J Infect Dis 2000; 31:1134-8.
  • 111. Matsumoto Y., Ikemoto A., Wakai Y., et al. Mechanism of therapeutic effectiveness of cefixime against typhoid fever. Antimicrob. Agents Chemother 2001; 45:2450-4.
  • 112. Memon I.A., Billo A.G., Memon I.I.I. Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children. South. Med. J. 1997; 90:1204-7.
  • 113. Girgis N.I., Sultan Y., Hammad O., Farid Z. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. Pediatr Infect Dis J 1995; 14(7):603-5.
  • 114. Smith M.D., Duong N.M., Hoa N.T.T., et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob. Agents Chemother. 1994; 38:1716-20.
  • 115. Bhutta Z.A., Khan I.A., Shadmani M. Failure of shortcourse ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob. Agent Chemother 2000; 44:450-2.
  • 116. Malkin D., Koren G., Saunders E.F. Drug-induced ap­lastic anemia: pathogenesis and clinical aspects. Am J Pediatr Hematol Oncol. 1990; 4:402-10.
  • 117. Hardman J.G., Limbird L.E., Gilman A.G. In: Gilman A.G., ed. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGrawHill, 2001; p.1249.
  • 118. Acharya G.P., Davis T.M.E., Ho M., et al. Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fiver. J Antimicrob Chemother 1997; 40:91-8.
  • 119. Parry C.M. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg 2004; 98:413-22.
  • 120. Finkelstein R., Markel C., Putterman A., et al. Waterbone typhoid fever in Haifa, Israel: clinical, microbiologic and therapeutic aspects of a major outbreack. Am J Med Sci 1988; 296:27-32.
  • 121. Hien T.T., Bethell D.B., Hoa N.T.T., et al. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 1995; 20:917-23.
  • 122. Bethell D.B., Day N.P.J., Dung N.M., et al. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob. Agent Chemother 1996; 40:2167-72.
  • 123. Gasem M.H., Keuter M., Dolmans W.M.V., et al. Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever. Antimicrob Agents Chemother. 2003; 47:1727-31.
  • 124. Yee C.L., Duffy C., Gerbino P.G., et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002; 21:525- 9.
  • 125. Thaver D., Zaidi A.K., Critchley J., Madni S.A., Bhutta Z.A. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst. Rev. 2005. Apr 18; (2):CD004530.
  • 126. Girgis N.I., Butler T., Frenck R.W., et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that includes patients with multidrug resistance. Antimicrob Agents Chemother 1999; 43:1441-4.
  • 127. Butler T., Frenck R.W., Johnson R.B., Khakhria R. In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula. J Antimicrob Chemother 2001; 47(4):455-8.
  • 128. Butler T., Sridhar C.B., Daga M.K., Johnson R.B., et al. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother 1999; 44:243-50.
  • 129. Parry C.M., Ho V.A., Phuong L.T., et al. Randomized controlled comparison of ofloxacin, azithromycin and ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistante typhoid fever. Antimicrob Agent Chemother 2007; 51:819-25.
  • 130. Koc E., Turkyilmaz C., Atalay Y., Sen E. Imipenem for treatment of relapsing Salmonella meningitis in a newborn infant. Acta Paediatr Jpn 1997; 39:624-5.
  • 131. Digranes A., Solberg C.O., Sjursen H., et al. Antibiotic susceptibility of blood culture isolates of Enterobacteriaceae from six Norwegian hospitals 1991-1992. APMIS 1997; 105:854-60.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились